, Won-Young Lee*
Department of Endocrinology and Metabolism, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
Copyright © 2026 Korean Society of Cardio-cerebrovascular Disease Prevention; Korean Society of Cardiovascular Pharmacotherapy.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Author contributions
Conceptualization: all authors; Data curation: EJR; Formal analysis: EJR; Investigation: EJR; Methodology: all authors; Supervision: WYL; Writing–original draft: EJR; Writing–review & editing: all authors. All authors read and approved the final manuscript.
Conflicts of interest
The authors have no conflicts of interest to declare.
Funding
The authors received no financial support for this study.
Acknowledgments
The authors used Claude (Anthropic) for manuscript drafting, language editing, and journal-style formatting; and SciSpace (Pubgenius Inc) for reference cross-checking. Artificial intelligence was not used for the study design, data analysis, or interpretation. The authors verified all content and references and take full responsibility for the work.
Values are presented as mean±standard deviation or number (%). P-values were derived from one-way analysis of variance for continuous variables and the chi-square test for categorical variables.
ALT, alanine aminotransferase; ASV, average successive variability; HDL-C, high-density lipoprotein cholesterol.
a)Waist circumference was available for 737 participants.
ASV was categorized into quartiles from Q1 (lowest) to Q4 (highest). Incidence is the cumulative proportion developing MASLD during follow-up. Over 13,897 person-years, the overall incidence rate was 37.8 per 1,000 person-years. Model 1 was adjusted for age, sex, baseline body mass index, systolic blood pressure, and fasting glucose. Model 2 was adjusted for model 1 covariates plus net weight change (fifth-visit weight minus first-visit weight). Model 3 (sensitivity analysis) was adjusted for model 2 covariates plus smoking status, frequency of alcohol consumption, triglycerides, high-density lipoprotein cholesterol, and baseline alanine aminotransferase. In model 2, net weight change was independently associated with incident MASLD (aHR, 1.11 per kg; 95% CI, 1.09–1.13; P for trend=0.022).
aHR, adjusted hazard ratio; ASV, average successive variability; CI, confidence interval; MASLD, metabolic dysfunction–associated steatotic liver disease.
| Characteristic | ASV quartile | P-value | |||
|---|---|---|---|---|---|
| Q1 (n=415) | Q2 (n=422) | Q3 (n=416) | Q4 (n=411) | ||
| Age (yr) | 39.7±5.2 | 38.9±5.5 | 38.0±4.8 | 37.7±5.6 | <0.001 |
| Male sex | 184 (44.3) | 210 (49.8) | 229 (55.0) | 223 (54.3) | 0.007 |
| Body mass index (kg/m²) | 21.7±2.6 | 22.1±2.5 | 22.5±2.4 | 23.6±2.8 | <0.001 |
| Waist circumference (cm)a) | 76.0±7.5 | 77.7±7.3 | 79.1±7.3 | 81.0±7.5 | <0.001 |
| Body weight ASV (kg) | 0.95±0.25 | 1.57±0.15 | 2.22±0.25 | 3.76±1.22 | <0.001 |
| Systolic blood pressure (mmHg) | 110.2±12.2 | 111.5±12.0 | 112.0±12.1 | 113.1±12.4 | 0.008 |
| HDL-C level (mg/dL) | 59.0±13.1 | 57.2±13.4 | 56.9±13.5 | 56.4±12.6 | 0.024 |
| ALT level (IU/L) | 17.9±9.9 | 19.3±11.3 | 20.0±11.2 | 21.2±15.5 | 0.001 |
| ASV quartile | No. of events | Incidence (%) | aHR (95% CI) | ||
|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | |||
| Q1 (n=415) | 87 | 21.0 | 1 (Reference) | 1 (Reference) | 1 (Reference) |
| Q2 (n=422) | 118 | 28.0 | 1.32 (1.00–1.74) | 1.27 (0.96–1.68) | 1.06 (0.79–1.43) |
| Q3 (n=416) | 133 | 32.0 | 1.43 (1.09–1.88) | 1.36 (1.03–1.79) | 1.18 (0.89–1.58) |
| Q4 (n=411) | 187 | 45.5 | 1.64 (1.25–2.14) | 1.40 (1.06–1.84) | 1.33 (1.00–1.77) |
Values are presented as mean±standard deviation or number (%). P-values were derived from one-way analysis of variance for continuous variables and the chi-square test for categorical variables. ALT, alanine aminotransferase; ASV, average successive variability; HDL-C, high-density lipoprotein cholesterol. a)Waist circumference was available for 737 participants.
ASV was categorized into quartiles from Q1 (lowest) to Q4 (highest). Incidence is the cumulative proportion developing MASLD during follow-up. Over 13,897 person-years, the overall incidence rate was 37.8 per 1,000 person-years. Model 1 was adjusted for age, sex, baseline body mass index, systolic blood pressure, and fasting glucose. Model 2 was adjusted for model 1 covariates plus net weight change (fifth-visit weight minus first-visit weight). Model 3 (sensitivity analysis) was adjusted for model 2 covariates plus smoking status, frequency of alcohol consumption, triglycerides, high-density lipoprotein cholesterol, and baseline alanine aminotransferase. In model 2, net weight change was independently associated with incident MASLD (aHR, 1.11 per kg; 95% CI, 1.09–1.13; P for trend=0.022). aHR, adjusted hazard ratio; ASV, average successive variability; CI, confidence interval; MASLD, metabolic dysfunction–associated steatotic liver disease.